Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel A Piris

Showing results (161-170 of 231) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2013
NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cellsLina Odqvist, Margarita Sánchez-Beato, Santiago Montes-Moreno, et al.
Nature Genetics|January 14, 2014
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomasTeresa Palomero, Lucile Couronné, Hossein Khiabanian, et al.
Haematologica|January 2, 2015
Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activationArantza Onaindia, Sagrario Gómez, Miguel Piris-Villaespesa, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 28, 2012
EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activationSantiago Montes-Moreno, Lina Odqvist, Julio A Diaz-Perez, et al.
Cancer|March 21, 2014
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramChi Young Ok, Zijun Y Xu-Monette, Alexandar Tzankov, et al.
Leukemia & Lymphoma|December 22, 2011
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group seriesPablo Guisado-Vasco, Reyes Arranz-Saez, Miguel Canales, et al.
Haematologica|October 12, 2014
Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomasRebeca Manso, Socorro M Rodríguez-Pinilla, Julia González-Rincón, et al.
Blood|January 24, 2015
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic featuresAlberto J Arribas, Andrea Rinaldi, Afua A Mensah, et al.
Haematologica|July 18, 2012
Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomasEsperanza Martín-Sánchez, Socorro M Rodríguez-Pinilla, Margarita Sánchez-Beato, et al.
Blood|May 19, 2010
Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma GroupMarta Salido, Cristina Baró, David Oscier, et al.
Pageof 24

Showing results (161-170 of 231) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2013
NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cellsLina Odqvist, Margarita Sánchez-Beato, Santiago Montes-Moreno, et al.
Nature Genetics|January 14, 2014
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomasTeresa Palomero, Lucile Couronné, Hossein Khiabanian, et al.
Haematologica|January 2, 2015
Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activationArantza Onaindia, Sagrario Gómez, Miguel Piris-Villaespesa, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 28, 2012
EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activationSantiago Montes-Moreno, Lina Odqvist, Julio A Diaz-Perez, et al.
Cancer|March 21, 2014
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramChi Young Ok, Zijun Y Xu-Monette, Alexandar Tzankov, et al.
Leukemia & Lymphoma|December 22, 2011
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group seriesPablo Guisado-Vasco, Reyes Arranz-Saez, Miguel Canales, et al.
Haematologica|October 12, 2014
Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomasRebeca Manso, Socorro M Rodríguez-Pinilla, Julia González-Rincón, et al.
Blood|January 24, 2015
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic featuresAlberto J Arribas, Andrea Rinaldi, Afua A Mensah, et al.
Haematologica|July 18, 2012
Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomasEsperanza Martín-Sánchez, Socorro M Rodríguez-Pinilla, Margarita Sánchez-Beato, et al.
Blood|May 19, 2010
Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma GroupMarta Salido, Cristina Baró, David Oscier, et al.
Pageof 24